Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease... see more

TSX:SZLS - Post Discussion

StageZero Life Sciences Ltd > Great financials. Confusing call and roll out
View:
Post by LithLover on Apr 02, 2021 10:09am

Great financials. Confusing call and roll out

Looking at Q4 the numbers are very good.  They had nearly 3 million in revenue and nearly 7 million in cash.  Tripp has said the last few quarters were on a trajectory so 4-5 million for q1 coming on May 17 probably not out of the question. We are already in Q2 (April-June) so probably expect another 4-5 million if not more.  So from a financial point of view easy to see 8-10 million over the next 6 months and cash in the bank.   Question is what does he do with it.  


The prospectus said a couple million on marketing.  Is that still to come?    If they buy these clinics it's an all share deal so cash is still there.  Why not cash and shares.  Makes me thing he has plans for the cash or at least has enough to last years here. 


Now I think most shareholders were hoping for something similar to EXAS where Mercer or physicians or health care groups would be ordering tests for their patients direct from our site.  Physician groups could order direct and employers and certain groups (fire fighters) could order from the site.   Tripp mention regulator issues so maybe that wasn't doable. So instead he's looking at a series of clinics  ok we get that but why HC and not just partner with a large and more well know group or even large hospital or health care group to start first   Why a less know group to test out the roll out?

What we need clarification on is HC Companies.  Who are they? How many clinics? What's their current patient numbers and reach etc?  Basically what are we buying for 15-23 million shares? And why them?

Tripp talked about this AVRT program
like we all should know it.  What is it?  How do you get in it?  Who can refer to it?  Again how many patients are in it and what's its reach?  

And in general this is what I think Noel wanted to know.   What's the process for the general public. If I live in the US and have the $1500 and want to be tested what do I or my doctor need to do    Same in Canada ?  Do I have to show symptoms of cancer or be sick to get tested?   Can referrals be made to AVRT?   Will mercer be using AVRT ?   How are companies that Tripp said that we wanted to partner with in Covid and all the Intake forms we saw, how do they get Aristotle?  


The excitement for the potential we all saw around Aristotle was that any person who wanted to know if they had cancer could get screened early using Aristotle. So do we all have to sign up to HC and AVRT as the only way to get tested?   And if so what's the process for the average joe and where and how can I do this ?    


Finally how will all this be communicated because if all of us who have been following this company for years and the our analyst for Clarus who has a vested interest are confused imagine all the physicians and patients and covid partner.  What's Mercers role in all this. 


We had great financials and are cashed up.   Tripp did well to pivot into Covid and likely made a good move with this looking at the future of health and his options.   He talks incremental growth but he wasn't clear on the process.  


He needs to clarify this right away so the market understands.  And he needs to spend some cash to market this if he expects adoption.  It was a major shift that many did not see coming    The call was not clear nor long enough to explain hence the sell off   We need more detail and clarification on how he intends to reach the masses here

Comment by Geraldo244 on Apr 02, 2021 10:28am
This post has been removed in accordance with Community Policy
Comment by LionWhisperer on Apr 02, 2021 10:36am
This post has been removed in accordance with Community Policy
Comment by InvrsContrarian on Apr 02, 2021 11:16am
There has been no change in the way stage has been doing business. They stated a few quarters ago they are a cash business model. Have cash will carry, which translates into Direct To Consumer. DTC The bashers will tell you otherwise. The financials tell the true story and stage is rocketing up to the sky with impressive revenue growth. Step by step this cash model brings buying power. Up until ...more  
Comment by Jabookie75 on Apr 02, 2021 10:45am
I'm most interested in what the value is of the 15-23 million shares we are shelling out for these labs.  We started 2020 with 33m shares out and end with over 60m.  Now we are headed to 75-83m.  Hopefully those new shares are issued at a fair price and not a fat discount which they can dump on us.
Comment by capebretongirl on Apr 02, 2021 11:10am
Comment by Mykndrsn on Apr 02, 2021 11:31am
Google Care Oncology. Lots of information about our new acquisition. Vertical integration and more revenue streams -  out the gate on Monday.
Comment by cactuseskimo on Apr 02, 2021 11:35am
That is an excellent write-up Lithlover and a very comprehensive explanation for what went wrong yesterday. There is definitely potential here, but those on this board dismissing others who may sell, while pumping up this strategy and viewing it through rose coloured glasses need to take a harder look and ask some tough questions first as you have so plainly laid out. When your mail analyst is ...more  
Comment by Nailbiter1 on Apr 02, 2021 11:56am
This post has been removed in accordance with Community Policy
Comment by skiboard09 on Apr 02, 2021 2:15pm
Biggest problem was the execution of what transpired yesterday.  Apparently there was actually uploading issues with SEDAR. Confirmed by the BCSC.  They just should of communicated better and maybe halted it till it got resolved.  also the tots flip in roll out of Aristotle I think caught people off gaurd and this new LOI reminds people of Oncore deal which has produced ...more  
Comment by Eoganacht on Apr 02, 2021 2:53pm
Great post. I note that Rebecca wrote "a partnership that offers multiple revenue streams and access to patients immediately" She didn't write "an exclusive partnership"  If it turns out that this is the only partnership SZLS needs to roll out Aristotle effectively then all the better. If additional partners are needed there's nothing stopping SZLS from pursuing ...more  
Comment by davewho on Apr 02, 2021 12:39pm
I hope we will see marketing for Aristotle and the new total patient care program/Avrt in the coming weeks. I listened to the CC again and James does say the market for Aristotle is huge but the market for a complete patient care system which includes Aristotle is many times the size of just Aristotle on its own. So many times the rev potential. Which seems to explain why they have pivoted to a ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities